Your session is about to expire
← Back to Search
GLP-1 Receptor Agonist
Semaglutide for Obesity
Phase 4
Waitlist Available
Research Sponsored by Novo Nordisk A/S
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
1. The parent(s) or legally acceptable representative (LAR) of the participant must sign and date the Informed Consent Form, according to local requirements
2. The participant must sign and date the Child Assent Form or provide oral assent, according to local requirements
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from 1.5 years to 3 years and end of continued treatment phase (up to 6 years)
Awards & highlights
Summary
The study is testing how well semaglutide can help adolescents with excess body weight to lose weight and to maintain weight loss. All participants in the study will receive semaglutide as a weekly injection. The study medicine is injected with a thin needle in the stomach, thighs or upper arms. All participants will get semaglutide treatment for a minimum of 3 years.
Who is the study for?
This trial is for teenagers with excess body weight who are interested in losing and maintaining weight loss. Participants will receive weekly injections of semaglutide for at least 3 years. Specific eligibility criteria details were not provided.
What is being tested?
The study focuses on the effectiveness of semaglutide, administered through weekly injections, in helping overweight adolescents lose and maintain their weight over a minimum period of three years.
What are the potential side effects?
Potential side effects from semaglutide may include digestive issues like nausea or diarrhea, possible injection site reactions, and changes in appetite. More specific side effect information was not provided.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ from 1.5 years to 3 years and end of continued treatment phase (up to 6 years)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from 1.5 years to 3 years and end of continued treatment phase (up to 6 years)
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Maintenance of Body Mass Index (BMI) below obesity threshold
Secondary study objectives
Achieving Body Mass Index (BMI) below obesity threshold
Achieving any improvement in Body Mass Index (BMI) category
Body Mass Index (BMI) percentage of the 95th percentile
+17 moreSide effects data
From 2020 Phase 4 trial • 104 Patients • NCT0418984821%
Nausea
12%
Decreased Appetite
100%
80%
60%
40%
20%
0%
Study treatment Arm
Overall Study
Trial Design
1Treatment groups
Experimental Treatment
Group I: SemaglutideExperimental Treatment1 Intervention
2.4mg or maximum tolerated dose(MTD) injected subcutaneously (under the skin, s.c) once weekly
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Semaglutide
2021
Completed Phase 4
~5160
Find a Location
Who is running the clinical trial?
Novo Nordisk A/SLead Sponsor
1,534 Previous Clinical Trials
2,422,358 Total Patients Enrolled
149 Trials studying Obesity
132,752 Patients Enrolled for Obesity
Clinical Transparency (dept. 2834)Study DirectorNovo Nordisk A/S
119 Previous Clinical Trials
143,167 Total Patients Enrolled
35 Trials studying Obesity
50,122 Patients Enrolled for Obesity
Share this study with friends
Copy Link
Messenger